Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Operating Leases (2019 - 2025)

Apyx Medical's Operating Leases history spans 7 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 0.56% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, down 0.56%, while the annual FY2025 figure was $4.5 million, 0.56% down from the prior year.
  • Operating Leases reached $4.5 million in Q4 2025 per APYX's latest filing, up from $4.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.4 million in Q2 2023 to a low of $30000.0 in Q3 2021.
  • Average Operating Leases over 5 years is $3.0 million, with a median of $4.3 million recorded in 2025.
  • Peak YoY movement for Operating Leases: crashed 80.39% in 2021, then surged 1413.33% in 2022.
  • A 5-year view of Operating Leases shows it stood at $30000.0 in 2021, then surged by 1466.67% to $470000.0 in 2022, then surged by 941.7% to $4.9 million in 2023, then decreased by 8.44% to $4.5 million in 2024, then dropped by 0.56% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Operating Leases are $4.5 million (Q4 2025), $4.2 million (Q3 2025), and $4.3 million (Q2 2025).